●药闻快报▲关注药财社聚焦医药界▲1诺诚健华奥布替尼SLE研究达主要终点12月14日,诺诚健华宣布其自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(SLE)的IIb期临床研究达到主要终点,并已获批准开展III期注册临床试验。公司将尽快启动该临床研究。系统性红斑狼疮是一种累及多系统的自身免疫性疾病,全球患者约800万,中国患者约100万,总数居全球第一。SLE常见于年轻及中年女性,疾病需长期管理,...
Source Link●药闻快报▲关注药财社聚焦医药界▲1诺诚健华奥布替尼SLE研究达主要终点12月14日,诺诚健华宣布其自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(SLE)的IIb期临床研究达到主要终点,并已获批准开展III期注册临床试验。公司将尽快启动该临床研究。系统性红斑狼疮是一种累及多系统的自身免疫性疾病,全球患者约800万,中国患者约100万,总数居全球第一。SLE常见于年轻及中年女性,疾病需长期管理,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.